Matches in SemOpenAlex for { <https://semopenalex.org/work/W2262071738> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2262071738 endingPage "12" @default.
- W2262071738 startingPage "408" @default.
- W2262071738 abstract "Skin rash is a predictable and manageable side effect of anti-EGFR therapy such as cetuximab. The aim of this study is to estimate the costs for the foreseeable management of skin toxicity in patients treated with cetuximab in our institute in order to assess the direct medical economic impact.We retrospectively analyzed all consecutive patients with advanced colorectal cancer treated with cetuximab at our institute from June 2006 to May 2011. We evaluated the severity and mean duration of skin rash for each grade and we identified the costs for the different therapeutic interventions. Patients were treated according to the general consensus management of skin toxicity associated with cetuximab treatment.We evaluated 31 patients. The median follow-up was 28.95 months (range, 1.84-75.49). At last follow-up 10 patients (32.3%) were alive with metastases, 18 patients (58.1%) had died, 1 patient (3.2%) was alive without evidence of disease, and 2 patients (6.5%) were lost to follow-up. The median progression-free survival was 8.26 months and the median overall survival 32.89 months. Nineteen patients (61.3%) developed skin toxicities: 7 patients (22.6%) grade 1, 9 patients (29.0%) grade 2, 3 patients (9.7%) grade 3; no grade 4 skin toxicity was observed. The median duration of grade 1 toxicity was 79 days (no specific treatments were started), of grade 2 toxicity 95 days (cost range, € 199.50-294.50) and of grade 3 toxicity 64 days (cost range, € 159.42-233.90).Our experience, through the analysis of nonselected cases, showed that the management of skin toxicities related to cetuximab is not so expensive. We recommend proper care of low-grade toxicities in order to reduce progression to high-grade toxicities and the resulting risk of hospitalization, which really impacts on costs." @default.
- W2262071738 created "2016-06-24" @default.
- W2262071738 creator A5027012799 @default.
- W2262071738 creator A5031199277 @default.
- W2262071738 creator A5044009241 @default.
- W2262071738 creator A5068497911 @default.
- W2262071738 creator A5082091985 @default.
- W2262071738 date "2012-10-12" @default.
- W2262071738 modified "2023-09-24" @default.
- W2262071738 title "The management of skin toxicity during cetuximab treatment in advanced colorectal cancer: how much does it cost? A retrospecive economic assessment from a single-center experience." @default.
- W2262071738 cites W1959598232 @default.
- W2262071738 cites W1967218337 @default.
- W2262071738 cites W1975209104 @default.
- W2262071738 cites W2002019750 @default.
- W2262071738 cites W2031520822 @default.
- W2262071738 cites W2068937134 @default.
- W2262071738 cites W2077950012 @default.
- W2262071738 cites W2095201384 @default.
- W2262071738 cites W2099865988 @default.
- W2262071738 cites W2112845420 @default.
- W2262071738 cites W2113302375 @default.
- W2262071738 cites W2120496760 @default.
- W2262071738 cites W2125016718 @default.
- W2262071738 cites W2137669069 @default.
- W2262071738 cites W2142564546 @default.
- W2262071738 cites W2151730005 @default.
- W2262071738 cites W2155311724 @default.
- W2262071738 cites W2155384808 @default.
- W2262071738 cites W2160503783 @default.
- W2262071738 cites W2161575448 @default.
- W2262071738 doi "https://doi.org/10.1700/1146.12632" @default.
- W2262071738 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23052154" @default.
- W2262071738 hasPublicationYear "2012" @default.
- W2262071738 type Work @default.
- W2262071738 sameAs 2262071738 @default.
- W2262071738 citedByCount "2" @default.
- W2262071738 countsByYear W22620717382018 @default.
- W2262071738 crossrefType "journal-article" @default.
- W2262071738 hasAuthorship W2262071738A5027012799 @default.
- W2262071738 hasAuthorship W2262071738A5031199277 @default.
- W2262071738 hasAuthorship W2262071738A5044009241 @default.
- W2262071738 hasAuthorship W2262071738A5068497911 @default.
- W2262071738 hasAuthorship W2262071738A5082091985 @default.
- W2262071738 hasConcept C121608353 @default.
- W2262071738 hasConcept C126322002 @default.
- W2262071738 hasConcept C141071460 @default.
- W2262071738 hasConcept C2778570526 @default.
- W2262071738 hasConcept C2779998722 @default.
- W2262071738 hasConcept C29730261 @default.
- W2262071738 hasConcept C526805850 @default.
- W2262071738 hasConcept C71924100 @default.
- W2262071738 hasConceptScore W2262071738C121608353 @default.
- W2262071738 hasConceptScore W2262071738C126322002 @default.
- W2262071738 hasConceptScore W2262071738C141071460 @default.
- W2262071738 hasConceptScore W2262071738C2778570526 @default.
- W2262071738 hasConceptScore W2262071738C2779998722 @default.
- W2262071738 hasConceptScore W2262071738C29730261 @default.
- W2262071738 hasConceptScore W2262071738C526805850 @default.
- W2262071738 hasConceptScore W2262071738C71924100 @default.
- W2262071738 hasIssue "4" @default.
- W2262071738 hasLocation W22620717381 @default.
- W2262071738 hasOpenAccess W2262071738 @default.
- W2262071738 hasPrimaryLocation W22620717381 @default.
- W2262071738 hasRelatedWork W1849106730 @default.
- W2262071738 hasRelatedWork W1974386387 @default.
- W2262071738 hasRelatedWork W1990026184 @default.
- W2262071738 hasRelatedWork W2368617189 @default.
- W2262071738 hasRelatedWork W2409947706 @default.
- W2262071738 hasRelatedWork W2590193187 @default.
- W2262071738 hasRelatedWork W2619302917 @default.
- W2262071738 hasRelatedWork W2884841735 @default.
- W2262071738 hasRelatedWork W4254024427 @default.
- W2262071738 hasRelatedWork W2519012089 @default.
- W2262071738 hasVolume "98" @default.
- W2262071738 isParatext "false" @default.
- W2262071738 isRetracted "false" @default.
- W2262071738 magId "2262071738" @default.
- W2262071738 workType "article" @default.